{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:52:11Z","timestamp":1780649531348,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chiasma Inc.","award":["Chiasma Inc."],"award-info":[{"award-number":["Chiasma Inc."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Results are presented from 2 to 3 trials investigating oral octreotide capsules (OOC) as an alternative to injectable somatostatin receptor ligands (iSRLs) in the treatment of acromegaly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CH-ACM-01 was an open-label trial (N\u2009=\u2009155) and CHIASMA OPTIMAL was a double-blind placebo-controlled (DPC) trial (N\u2009=\u200956), both investigating OOC as maintenance therapy for patients with acromegaly who were biochemical responders receiving iSRLs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline characteristics in both trials reflected those expected of patients with acromegaly responding to treatment and were similar between trials, despite differences in inclusion criteria. OOC demonstrated a consistent degree of biochemical response across trials, with 65% of patients in CH-ACM-01 maintaining response during the core period and 64% of patients in CHIASMA OPTIMAL at the end of the DPC. Mean insulin-like growth factor I (IGF-I) levels remained within inclusion criteria at the end of treatment in both trials. Of 110 patients entering the fixed-dose phase in CH-ACM-01, 80% maintained or improved acromegaly symptoms from baseline to the end of treatment. Over 85% of patients in both trials elected to continue into the extension phases. OOC were found to be well tolerated across both trials, and no dose-related adverse events were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>OOC demonstrated remarkably consistent results for biochemical response, durability of response, and preference to continue with oral treatment across these 2 complementary landmark phase 3 trials, despite differences in the design of each.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial registration<\/jats:bold>\n                      NCT03252353 (August 2017), NCT01412424 (August 2011).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-021-01163-2","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T12:03:09Z","timestamp":1624622589000},"page":"943-953","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results"],"prefix":"10.1007","volume":"24","clinical-trial-number":[{"clinical-trial-number":"nct03252353","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01412424","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Artak","family":"Labadzhyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L B","family":"Nachtigall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":false,"given":"M","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M B","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Molitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-7093","authenticated-orcid":false,"given":"S L","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-488X","authenticated-orcid":false,"given":"Y","family":"Greenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5817-3594","authenticated-orcid":false,"given":"N","family":"Biermasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2360-6596","authenticated-orcid":false,"given":"M","family":"Bolanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Haviv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Ludlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Patou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7905-7357","authenticated-orcid":false,"given":"C J","family":"Strasburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"1163_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/ep.17.s4.1","volume":"17","author":"L Katznelson","year":"2011","unstructured":"Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK (2011) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly\u20132011 update. Endocr Pract 17:1\u201344. https:\/\/doi.org\/10.4158\/ep.17.s4.1","journal-title":"Endocr Pract"},{"key":"1163_CR2","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JAH (2014) Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 99:3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"key":"1163_CR3","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1172\/jci39375","volume":"119","author":"S Melmed","year":"2009","unstructured":"Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119:3189\u20133202. https:\/\/doi.org\/10.1172\/jci39375","journal-title":"J Clin Invest"},{"key":"1163_CR4","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","volume":"382","author":"S Melmed","year":"2020","unstructured":"Melmed S (2020) Pituitary-tumor endocrinopathies. N Engl J Med 382:937\u2013950. https:\/\/doi.org\/10.1056\/NEJMra1810772","journal-title":"N Engl J Med"},{"key":"1163_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1530\/eje-15-1042","volume":"174","author":"CJ Strasburger","year":"2016","unstructured":"Strasburger CJ, Karavitaki N, St\u00f6rmann S, Trainer PJ, Kreitschmann-Andermahr I, Droste M, Korbonits M, Feldmann B, Zopf K, Sanderson VF, Schwicker D, Gelbaum D, Haviv A, Bidlingmaier M, Biermasz NR (2016) Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur J Endocrinol 174:355\u2013362. https:\/\/doi.org\/10.1530\/eje-15-1042","journal-title":"Eur J Endocrinol"},{"key":"1163_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s11102-010-0282-z","volume":"14","author":"M Fleseriu","year":"2011","unstructured":"Fleseriu M (2011) Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary 14:184\u2013193. https:\/\/doi.org\/10.1007\/s11102-010-0282-z","journal-title":"Pituitary"},{"key":"1163_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"Gadelha MR, Kasuki L, Lim DST, Fleseriu M (2019) Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev 40:268\u2013332. https:\/\/doi.org\/10.1210\/er.2018-00115","journal-title":"Endocr Rev"},{"key":"1163_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","volume":"5","author":"A Colao","year":"2019","unstructured":"Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, Pivonello R (2019) Acromegaly Nat Rev Dis Primers 5:20. https:\/\/doi.org\/10.1038\/s41572-019-0071-6","journal-title":"Acromegaly Nat Rev Dis Primers"},{"key":"1163_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11102-020-01038-y","volume":"23","author":"M Fleseriu","year":"2020","unstructured":"Fleseriu M, Fogelfeld L, Gordon MB, Sisco J, Crosby RD, Ludlam WH, Haviv A, Mathias SD (2020) An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies. Pituitary 23:347\u2013358. https:\/\/doi.org\/10.1007\/s11102-020-01038-y","journal-title":"Pituitary"},{"key":"1163_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Lely AJ, Melmed S (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24:1\u201313","journal-title":"Pituitary"},{"key":"1163_CR11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11102-016-0737-y","volume":"20","author":"DS Lim","year":"2017","unstructured":"Lim DS, Fleseriu M (2017) The role of combination medical therapy in the treatment of acromegaly. Pituitary 20:136\u2013148. https:\/\/doi.org\/10.1007\/s11102-016-0737-y","journal-title":"Pituitary"},{"key":"1163_CR12","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1210\/jc.2013-3757","volume":"99","author":"JD Carmichael","year":"2014","unstructured":"Carmichael JD, Bonert VS, Nu\u00f1o M, Ly D, Melmed S (2014) Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab 99:1825\u20131833. https:\/\/doi.org\/10.1210\/jc.2013-3757","journal-title":"J Clin Endocrinol Metab"},{"key":"1163_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/jim-2017-000570","volume":"66","author":"S Liu","year":"2018","unstructured":"Liu S, Adelman DT, Xu Y, Sisco J, Begelman SM, Webb SM, Badia X, Thethi TK, Fonseca V, Shi L (2018) Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly. J Investig Med 66:653\u2013660. https:\/\/doi.org\/10.1136\/jim-2017-000570","journal-title":"J Investig Med"},{"key":"1163_CR14","doi-asserted-by":"publisher","first-page":"GP151","DOI":"10.1530\/endoabs.41.GP151","volume":"41","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Melmed S, Mangal B, Strasburger CJ, Biermasz NR (2016) Longitudinal assessment of response to treatment with oral octreotide capsules in patients with acromegaly: post-hoc analysis of a phase 3 trial. Endocrine Abstracts 41:GP151. https:\/\/doi.org\/10.1530\/endoabs.41.GP151","journal-title":"Endocrine Abstracts"},{"key":"1163_CR15","doi-asserted-by":"publisher","first-page":"627711","DOI":"10.3389\/fendo.2021.627711","volume":"12","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Molitch M, Dreval A, Biermasz NR, Gordon MB, Crosby RD, Ludlam WH, Haviv A, Gilgun-Sherki Y, Mathias SD (2021) Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands. Front Endocrinol (Lausanne) 12:627711","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1163_CR16","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1210\/jc.2012-1179","volume":"97","author":"S Tuvia","year":"2012","unstructured":"Tuvia S, Atsmon J, Teichman SL, Katz S, Salama P, Pelled D, Landau I, Karmeli I, Bidlingmaier M, Strasburger CJ, Kleinberg DL, Melmed S, Mamluk R (2012) Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab 97:2362\u20132369. https:\/\/doi.org\/10.1210\/jc.2012-1179","journal-title":"J Clin Endocrinol Metab"},{"key":"1163_CR17","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1007\/s11095-014-1303-9","volume":"31","author":"S Tuvia","year":"2014","unstructured":"Tuvia S, Pelled D, Marom K, Salama P, Levin-Arama M, Karmeli I, Idelson GH, Landau I, Mamluk R (2014) A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms. Pharm Res 31:2010\u20132021. https:\/\/doi.org\/10.1007\/s11095-014-1303-9","journal-title":"Pharm Res"},{"key":"1163_CR18","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1210\/jc.2014-4113","volume":"100","author":"S Melmed","year":"2015","unstructured":"Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K, Glaser B, Goth M, Greenman Y, Trainer P, Mezosi E, Shimon I, Giustina A, Korbonits M, Bronstein MD, Kleinberg D, Teichman S, Gliko-Kabir I, Mamluk R, Haviv A, Strasburger C (2015) Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab 100:1699\u20131708. https:\/\/doi.org\/10.1210\/jc.2014-4113","journal-title":"J Clin Endocrinol Metab"},{"key":"1163_CR19","doi-asserted-by":"publisher","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","volume":"105","author":"SL Samson","year":"2020","unstructured":"Samson SL, Nachtigall LB, Fleseriu M, Gordon MB, Bolanowski M, Labadzhyan A, Ur E, Molitch M, Ludlam WH, Patou G, Haviv A, Biermasz N, Giustina A, Trainer PJ, Strasburger CJ, Kennedy L, Melmed S (2020) Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide. J Clin Endocrinol Metab 105:e3785\u2013e3797. https:\/\/doi.org\/10.1210\/clinem\/dgaa526","journal-title":"J Clin Endocrinol Metab"},{"key":"1163_CR20","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1365-2265.2009.03668.x","volume":"72","author":"I Erotokritou-Mulligan","year":"2010","unstructured":"Erotokritou-Mulligan I, Eryl Bassett E, Cowan DA, Bartlett C, Milward P, Sartorio A, S\u00f6nksen PH, Holt RI (2010) The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score. Clin Endocrinol (Oxf) 72:520\u2013526","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1163_CR21","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1210\/jc.2003-032150","volume":"89","author":"D Milani","year":"2004","unstructured":"Milani D, Carmichael JD, Welkowitz J, Ferris S, Reitz RE, Danoff A, Kleinberg DL (2004) Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab 89:2271\u20132274. https:\/\/doi.org\/10.1210\/jc.2003-032150","journal-title":"J Clin Endocrinol Metab"},{"key":"1163_CR22","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1373\/clinchem.2008.105726","volume":"54","author":"TV Nguyen","year":"2008","unstructured":"Nguyen TV, Nelson AE, Howe CJ, Seibel MJ, Baxter RC, Handelsman DJ, Kazlauskas R, Ho KK (2008) Within-subject variability and analytic imprecision of insulinlike growth factor axis and collagen markers: Implications for clinical diagnosis and doping tests. Clin Chem 54:1268\u20131276","journal-title":"Clin Chem"},{"key":"1163_CR23","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/bcp.14265","volume":"86","author":"MJ van Esdonk","year":"2020","unstructured":"van Esdonk MJ, Burggraaf J, van der Graaf PH, Stevens J (2020) Model informed quantification of the feed-forward stimulation of growth hormone by growth hormone-releasing hormone. Br J Clin Pharmacol 86:1575\u20131584. https:\/\/doi.org\/10.1111\/bcp.14265","journal-title":"Br J Clin Pharmacol"},{"key":"1163_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11102-018-0884-4","volume":"21","author":"MJ van Esdonk","year":"2018","unstructured":"van Esdonk MJ, van Zutphen EJM, Roelfsema F, Pereira AM, van der Graaf PH, Biermasz NR, Stevens J, Burggraaf J (2018) How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. Pituitary 21:310\u2013322. https:\/\/doi.org\/10.1007\/s11102-018-0884-4","journal-title":"Pituitary"},{"key":"1163_CR25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1590\/S0004-27302010000500008","volume":"54","author":"PW Rosario","year":"2010","unstructured":"Rosario PW (2010) Normal values of serum IGF-1 in adults: results from a Brazilian population. Arquivos Brasileiros de Endocrinologia Metabologia 54:477\u2013481","journal-title":"Arquivos Brasileiros de Endocrinologia Metabologia"},{"key":"1163_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1046\/j.1365-2265.2000.00876.x","volume":"52","author":"C Skjaerbaek","year":"2000","unstructured":"Skjaerbaek C, Frystyk J, Kaal A, Laursen T, M\u00f8ller J, Weeke J, J\u00f8rgensen JO, Sandahl Christiansen J, Orskov H (2000) Circadian variation in serum free and total insulin-like growth factor (IGF)-I and IGF-II in untreated and treated acromegaly and growth hormone deficiency. Clin Endocrinol (Oxf) 52:25\u201333. https:\/\/doi.org\/10.1046\/j.1365-2265.2000.00876.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1163_CR27","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Res\u00e9ndiz K, Ruffin M, Chen Y, Sheppard M (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99:791\u2013799. https:\/\/doi.org\/10.1210\/jc.2013-2480","journal-title":"J Clin Endocrinol Metab"},{"key":"1163_CR28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11102-019-01013-2","volume":"23","author":"EB Geer","year":"2020","unstructured":"Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Gelbaum D, Liu S, Mathias SD, Shi L (2020) Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider. Pituitary 23:140\u2013148. https:\/\/doi.org\/10.1007\/s11102-019-01013-2","journal-title":"Pituitary"}],"updated-by":[{"DOI":"10.1007\/s11102-021-01177-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000}}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01163-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-021-01163-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01163-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T05:21:03Z","timestamp":1635225663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-021-01163-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1007\/s11102-021-01163-2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740380515.793587365","asserted-by":"object"}]},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"assertion":[{"value":"11 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11102-021-01177-w","URL":"https:\/\/doi.org\/10.1007\/s11102-021-01177-w","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AL reports no conflicts of interest. LBN served as research support for Chiasma and received grant support from and served as a consultant for Ipsen. MF received a research grant to Oregon Health and Science University as principal investigator for Crinetics, Chiasma, Ionis, Novartis, Recordati and served as a scientific consultant for Crinetics, Chiasma, Ionis, Ipsen, Novartis, Pfizer, and Recordati. MBG received research support from Chiasma, Corcept, Crinetics, Ipsen, Novartis, Opico, Pfizer, Strongbridge, Teva, and Novo Nordisk and served as a scientific consultant for Chiasma and Novo Nordisk. MM received research grant to institution from Chiasma, Novartis, and Crinetics and received a consultation honorarium from Chiasma. LK served as a clinical trial principal investigator for Chiasma and Ionis and served as a consultant for Pfizer. SLS served as site principal investigator, steering chair, and consultant for Chiasma and Novartis. YG received funding in the form of a research grant from Pfizer and was compensated for serving as principal investigator of research grants to Tel Aviv-Sourasky Medical Center from Chiasma and Strongbridge Biopharma, and also received consultation fees from Tiburio and lecture fees from CTS. NB reports no conflicts of interest.  MB received a research grant from Ispen and lecture fees from Ispen, Novartis, Pfizer, and Recordati, and also served as an advisory board member for Novartis, Pfizer, and Recordati. AH, WHL, GP are employees of Chiasma. CJS received consultancy fees and speaker honoraria from Chiasma, Pfizer, Ipsen, and Crinetics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This trial was performed in accordance with the principles stated in the Declaration of Helsinki. Prior to starting the trials, ethical approval was obtained for all protocols from the local Institutional Review Board or other appropriate ethics committee to confirm the trials meet national and international guidelines for research on humans.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the trials.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}